You are here

Teladoc Health Announces Availability of Best Doctors Oncology Insight in Canada

Now available to Sun Life Financial clients, Oncology Insight provides patients facing cancer access to the world’s leading oncologists, backed by recommended treatment options from IBM Watson for Oncology

TORONTO, Oct. 11, 2018 (GLOBE NEWSWIRE) -- Teladoc Health, the global leader in virtual care, announced today the availability of the Best Doctors Oncology Insight service in Canada. Oncology Insight enables individuals with a cancer diagnosis to receive an in-depth medical review from a world-renowned expert oncologist who has access to the cognitive computing capabilities of IBM Watson for Oncology. Oncology Insight is now available to Sun Life Assurance Company of Canada’s group benefits members who have Best Doctors Expert Medical Services through their Extended Health Care (EHC) plan.

“Providing our members with access to the finest medical expertise is a critical component to care," said JM Lavoie, assistant vice president, Product Development, Group Benefits, Sun Life Financial Canada. “Best Doctors Oncology Insight helps our members ensure their treatment options have been carefully reviewed and they’re receiving the best care for their diagnosis.”

According to the Canadian Cancer Society, about one in two Canadians will develop cancer in their lifetimes. With Oncology Insight, members facing cancer diagnoses can request a medical opinion by an expert oncologist who reviews medical records, retests pathology results, and reviews the latest clinical research using IBM Watson for Oncology. IBM Watson for Oncology is an AI decision support tool that complements the work of oncologists, supporting them in clinical decision-making by evaluating the patient’s clinical data, including dozens of clinical attributes relevant to the individual’s unique diagnosis. After thorough case review, the Best Doctors expert oncologist validates the diagnosis and provides the patient with evidence-based, personalized treatment recommendations.

“With Oncology Insight, experts can use augmented intelligence from IBM Watson for Oncology to create personalized treatment recommendations, empowering patients and physicians with actionable data that can help them make more informed decisions,” said Dr. Lewis Levy, chief medical officer, Teladoc Health. "With the peer-reviewed literature and evidence-based references that Watson presents, oncologists can quickly access and review treatment options that they may not have otherwise considered. We’re proud to work with Sun Life Financial to help their members diagnosed with cancer.”

For more information about Best Doctors Oncology Insight, visit https://bestdoctors.com/canada/.

About Teladoc Health
A mission-driven organization, Teladoc Health, Inc. is successfully transforming how people access and experience healthcare, with a focus on high quality, lower costs, and improved outcomes around the world. The company’s award-winning, integrated clinical solutions are inclusive of telehealth, expert medical services, AI and analytics, and licensable platform services. With more than 2,000 employees, the organization delivers care in 125 countries and in more than 20 languages, partnering with employers, hospitals and health systems, and insurers to transform care delivery. For more information, please visit www.teladochealth.com or follow @TeladocHealth on Twitter.

Media Contacts:
Justin Joseph
Director of Public Relations
Teladoc Health
617-359-5522
jjoseph@teladoc.com

 

Thursday, October 11, 2018 - 08:35

More Headlines

Vaccine Prevents Some Cancers, Diseases Caused by 9 HPV Types
In Future, Providers May Screen for APOE4 Before Treatment 
MIT Professor Working to Produce Thousands of Drugs on Demand
Agency Scrutinizes Attempts to Block Generics
Other Means Required to Measure Effectiveness of Expensive New Therapies 
First Drug Approved Under Agency’s LPAD Pathway
Sunshine Law Will be Expanded to Include Nurse Practitioners, Physician Assistants, Nurse-Midwives, and Others
European study concludes clinicians can safely switch patients from originators to biosimilars
Anti-abortionist and Republican Opposition Leads to Cancelation of Contract with Fetal Tissue Firm